BEND4: a novel prognostic biomarker in diffuse large B-cell lymphoma
Elevated BEND4 levels were linked to poor prognosis and chemoresistance in DLBCL, potentially due to transcriptional regulation and immune suppression roles. BEND4 may represent a viable therapeutic target in DLBCL.
Authors
- Lian-Yong Xi
- Yanfang Wang (ORCID: https://orcid.org/0009-0005-4890-0651)
- Hua Wang (ORCID: https://orcid.org/0000-0002-2605-5697)
- Zhenghao Zhang (ORCID: https://orcid.org/0000-0002-4488-2688)
- Fei Dong (ORCID: https://orcid.org/0000-0002-7969-293X)
Institutions
- Peking University (CN)
- Peking University Third Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1007/s12672-025-02519-x
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China